

Mark S Shahin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8095849/publications.pdf>

Version: 2024-02-01

38
papers

2,539
citations

430874

18
h-index

377865

34
g-index

40
all docs

40
docs citations

40
times ranked

3090
citing authors

#	ARTICLE	IF	CITATIONS
1	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2391-2402.	27.0	1,337
2	A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. <i>Cancer Gene Therapy</i> , 2002, 9, 553-566.	4.6	171
3	Paclitaxel and Platinum Chemotherapy for Ovarian Carcinoma during Pregnancy. <i>Gynecologic Oncology</i> , 2001, 83, 599-600.	1.4	145
4	A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2011, 122, 111-115.	1.4	101
5	Anorectal dysfunction after surgical treatment for cervical cancer. <i>Journal of the American College of Surgeons</i> , 2002, 195, 513-519.	0.5	92
6	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
7	Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. <i>Cancer Gene Therapy</i> , 2002, 9, 567-572.	4.6	63
8	Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 127, 70-74.	1.4	61
9	A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). <i>Gynecologic Oncology</i> , 2018, 150, 247-252.	1.4	56
10	Failure of BRCA1 dysfunction to alter ovarian cancer survival. <i>Clinical Cancer Research</i> , 2002, 8, 1196-202.	7.0	56
11	A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2010, 116, 332-334.	1.4	44
12	A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2010, 118, 139-144.	1.4	40
13	A phase II evaluation of AMG 102 (rilatumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 132, 526-530.	1.4	40
14	Ovarian Mixed Germ Cell Tumor with Predominance of Polyembryoma: A Case Report with Literature Review. <i>International Journal of Gynecological Pathology</i> , 2002, 21, 78-81.	1.4	24
15	A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q). <i>Gynecologic Oncology</i> , 2011, 120, 454-458.	1.4	23
16	REPRODUCTIVE SEQUELAE OF CANCER TREATMENT. <i>Obstetrics and Gynecology Clinics of North America</i> , 1998, 25, 423-433.	1.9	21
17	Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6080-6085.	7.0	21
18	A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. <i>Gynecologic Oncology</i> , 2017, 144, 96-100.	1.4	21

#	ARTICLE	IF	CITATIONS
19	Disparities Among Cervical Cancer Patients Receiving Brachytherapy. <i>Obstetrics and Gynecology</i> , 2019, 134, 559-569.	2.4	19
20	p53 mutations and microsatellite instability in ovarian cancer: Yin and Yang. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 184, 891-903.	1.3	18
21	Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. <i>Gynecologic Oncology</i> , 2022, 166, 36-43.	1.4	18
22	Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. <i>Advances in Radiation Oncology</i> , 2019, 4, 579-586.	1.2	17
23	Phase II Evaluation of 3-Day Topotecan with Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer. <i>Gynecologic Oncology</i> , 2002, 85, 278-284.	1.4	16
24	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253.	1.4	15
25	Since surgery isn't getting any easier, why is reimbursement going down? An update from the SGO taskforce on coding and reimbursement. <i>Gynecologic Oncology</i> , 2017, 144, 235-237.	1.4	13
26	Implementation of an abdominal closure bundle to reduce surgical site infection in patients on a gynecologic oncology service undergoing exploratory laparotomy. <i>Gynecologic Oncology</i> , 2018, 149, 560-564.	1.4	9
27	The tell-tale heart: A case of recurrent vulvar carcinoma with cardiac metastasis and review of literature. <i>Gynecologic Oncology Reports</i> , 2017, 21, 20-23.	0.6	7
28	In vitro chemoresponse in metachronous pairs of ovarian cancers. <i>Anticancer Research</i> , 2014, 34, 7191-6.	1.1	4
29	SGO Health Policy and Socioeconomic Committee: Current and Future Efforts of the Coding and Reimbursement Taskforce and the Policy, Quality and Outcomes Taskforce. <i>Gynecologic Oncology</i> , 2016, 143, 229-230.	1.4	3
30	Implementation of an enhanced recovery protocol in gynecologic oncology. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100771.	0.6	3
31	Racial determinants of treatment delays in gynecologic malignancies. <i>Gynecologic Oncology</i> , 2021, 162, S60.	1.4	2
32	Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. <i>Gynecologic Oncology</i> , 2021, 162, S65.	1.4	2
33	Bevacizumab-induced bleeding in colorectal and noncolorectal cancer patients in a community oncology setting: An Abington Memorial Hospital experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18250-e18250.	1.6	1
34	Corrigendum to "A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study" [Gynecol. Oncol. 116 (2010)]. <i>Gynecologic Oncology</i> , 2010, 118, 208.	1.4	0
35	Changes to outpatient evaluation and management coding: 2021 will be a better year. <i>Gynecologic Oncology</i> , 2021, 161, 871-875.	1.4	0
36	Does ERAS implementation in gynecologic oncology result in acute kidney injury?. <i>Gynecologic Oncology</i> , 2021, 162, S141.	1.4	0

#	ARTICLE	IF	CITATIONS
37	In vitro chemoresponse in metachronous pairs of ovarian cancers.. Journal of Clinical Oncology, 2014, 32, e16520-e16520.	1.6	0
38	Primary Pelvic Papillary Thyroid Carcinoma with Metastases to Peritoneal Surfaces. American Surgeon, 2016, 82, 1148-1150.	0.8	0